The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Aug. 22, 2017

Filed:

Mar. 28, 2016
Applicant:

Roche Innovation Center Copenhagen A/s, Hoersholm, DK;

Inventors:

Joacim Elmen, Stockholm, SE;

Claes Wahlestedt, Stockholm, SE;

Zicai Liang, Sundbyberg, SE;

Anders M. Sorensen, Copenhagen, DK;

Henrik Orum, Vaerlose, DK;

Troels Koch, Copenhagen, DK;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C12N 15/113 (2010.01); A61K 38/09 (2006.01); A61K 38/20 (2006.01); A61K 38/21 (2006.01); A61K 38/31 (2006.01); C12N 15/11 (2006.01); A61K 38/00 (2006.01);
U.S. Cl.
CPC ...
C12N 15/1131 (2013.01); A61K 38/09 (2013.01); A61K 38/2013 (2013.01); A61K 38/212 (2013.01); A61K 38/31 (2013.01); C12N 15/111 (2013.01); C12N 15/1135 (2013.01); A61K 38/00 (2013.01); C12N 2310/14 (2013.01); C12N 2310/315 (2013.01); C12N 2310/3231 (2013.01); C12N 2310/3233 (2013.01); C12N 2310/3341 (2013.01); C12N 2310/53 (2013.01); C12N 2320/51 (2013.01); C12N 2330/30 (2013.01);
Abstract

The present invention is directed to novel double-stranded short interfering (siRNA) analogs comprising locked nucleic acid (LNA) monomers. Such compounds induces sequence-specific post-transcriptional gene silencing in many organisms by a process known as RNA interference (RNAi). The compounds disclosed herein has improved properties compared to non-modified siRNAs and may, accordingly, be useful as therapeutic agents, e.g., in the treatment of various cancer forms. More particularly, the present invention is directed to siRNA analogs comprising a sense strand and an antisense strand, wherein each strand comprises 12-35 nucleotides and wherein the siRNA analogs comprise at least one locked nucleic acid (LNA) monomer.


Find Patent Forward Citations

Loading…